AVB-620

· Avelas Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for AVB-620, covering 2017-03-22 to 2021-06-11. Get the full timeline:

Most recent: Clinical Trial Update: Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery [Phase 2]